Southern Shuanglin Bio-Pharmacy shareholders reappoint auditor for 2025

Southern Shuanglin Bio-Pharmacy convened its second extraordinary general meeting of shareholders for 2025 on September 8, 2025. The meeting, held in Shanghai and via online voting, was called to approve a proposal to reappoint the company's auditing institution for the 2025 financial year.

The proposal garnered significant support, with 99.6306% of the 382,211,909 total shares present voting in favor. Only 0.3330% (1,277,328 shares) voted against, and 0.0364% (139,783 shares) abstained. Retail investors, representing 52,210,636 shares, also largely supported the proposal, with 97.3575% in favor.

Beijing Jiayuan Law Firm confirmed the meeting's compliance with "Company Law" and "Rules for General Meetings of Shareholders," validating the meeting's convening, procedures, and the qualifications of attendees and conveners. The resolution, as outlined in the legal opinion, is deemed valid and effective.